After removing female sex hormones, the survival advantages of KRas;rankfl/fl females disappeared completely (Fig. 7C), and histological analysis revealed no difference in tumor burden between the female KRas;rank+/+ and KRas;rankfl/fl cohorts (Fig. 7D). Here, KRAS is linked to neoplasm.